Source: Circulation. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, v. 140, n. 2, p. 103-112, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038840. Acesso em: 16 out. 2024.APA
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Bregeault, M. -F., Dalby, A. J., et al. (2019). Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140( 2), 103-112. doi:10.1161/CIRCULATIONAHA.118.038840NLM
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 out. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840Vancouver
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 out. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840